Just reported
From Illumina's results release of 29. Oktober 2026; its quarterly report has since been filed.
Actual
1,13B $
+4,2 % y/y
-2,6 % q/q
Guided
—
No guide given
Actual
1,43 $
+46 % y/y
+5,9 % q/q
Guided
—
No guide given
Actual
305M $
+34 % y/y
+24 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Die Umsatzanteile sind Schätzungen für quarter ended 2026-03-31 und keine Zahlen aus einem eingereichten Bericht.
NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.
StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.
Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.
Gebaut aus den eigenen Einreichungen von Illumina, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
209,61 $-1,5 %Schluss 12. Nov.
Zahlen bis 27. September 2026, aus dem 10-Q vom 30. Oktober 2026
Illumina sells DNA-sequencing kits and machines to medical laboratories, hospitals, universities and drug companies.
The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 41 Quartalen der Notenhistorie von Illumina, Inc.. Die übrigen 39 reichen zurück bis November 2016.
